Reliance Industries Lt is getting into genetic mapping, looking to make a health care trend led by disruptive US startups like 23andMe more affordable and widespread in India’s growing consumer market. The energy-to-ecommerce conglomerate will roll out within weeks a comprehensive 12,000-rupee ($145) genome sequencing test, which is about 86% cheaper than other offerings available locally.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News
